[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
BACKGROUND
The knowledge of the importance, the physiopathological mechanisms, and the management of the chemotherapy-induced emesis has increased exponentially during the last 20 years. High-dosage metoclopramide (MCP) therapy has been introduced in the eighties and serotonine type-3 receptor antagonists (5-HT(3) antagonists) have been used since the late eighties and early nineties. Due to both classes of substances the results of the antiemetic therapies have improved drastically. After 20 years of intensive clinical research it seems to be appropriate to come to an intermediate conclusion.


METHODS
With the aid of an overview and a new analysis of the literature published on this topic so far, the current state of research is shown (including the fields in which further improvement will be necessary), and suggestions are made, wherever it seemed possible, to attain the "gold standard" in antiemetic therapy.


CONCLUSIONS
In connection with all highly or very highly emetogenic chemotherapies, an antiemetic prophylaxis should be initiated on the day of therapy, especially when using platinum or most of the cyclophosphamide-based regimes for cancer treatment. The recommended prophylaxis consists of a combination of 5-HT(3) antagonists with a corticosteroid. To combat the so-called delayed emesis on the days following therapy, all patients should undergo an oral corticoid therapy, possibly in combination with MCP (especially platinum-therapy patients), less frequently with 5-HT(3) antagonists. With these means of prophylaxis emesis can be prevented/avoided completely in most patients, and nausea can at least be reduced. It is sufficient to administer a single dose of 5-HT(3) antagonists prior to chemotherapy. For ondansetron and granisetron, the best documented substances within this class of drugs, 8 mg (ondansteron) and 3 mg (granisetron) are considered standard dosages. Among the corticoids, most data have been accumulated for dexamethasone. A standard dose of 10 to 20 mg can be administered prior to chemotherapy. Right after and especially on the days following chemotherapy higher dosages seem to be indicated.


CONCLUSIONS
Further therapy improvements, especially concerning emesis and nausea on the days following chemotherapy, are necessary and are currently object of clinical research.
Du Bois
A
A
Frauenklinik der St. Vincentius Krankenhäuser, Karlsruhe.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D019985:Benchmarking; D003907:Dexamethasone / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008787:Metoclopramide / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D017294:Ondansetron / Q000627:therapeutic use; D011292:Premedication; D016032:Randomized Controlled Trials as Topic; D012106:Research; D058831:Serotonin 5-HT3 Receptor Antagonists; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy*
D003907:Dexamethasone; D017829:Granisetron; D007211:Indoles; D008787:Metoclopramide; D017294:Ondansetron; D058831:Serotonin 5-HT3 Receptor Antagonists; D000077526:Tropisetron